Clinical Trial Update: Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating INBRX-106 with pembrolizumab for stage II/III triple-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• INBRX-106 (INBRX-106)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Providence Health & Services | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING